Early versus delayed cardioversion: why should we wait?

References

• Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):2667–2677.
   PubMed Web of Science ®Google Scholar
• Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825–1833.
   PubMed Web of Science ®Google Scholar
• Lafuente-Lafuente C, Valembois L, Bergmann JF, et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2015;2015(3):CD005049.
   Google Scholar
• Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834–1840.
   PubMed Web of Science ®Google Scholar
• Airaksinen KEJ, Grönberg T, Nuotio I, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol. 62(13): 1187–1192. 2013.
   PubMed Web of Science ®Google Scholar
• Hellman T, Kiviniemi T, Nuotio I, et al. Intensity of anticoagulation and risk of thromboembolism after elective cardioversion of atrial fibrillation. Thromb Res. 2017;156:163–167.
   PubMed Web of Science ®Google Scholar
• Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol. 1969;23(2):208–216.
   PubMed Web of Science ®Google Scholar
• Arnold AZ, Mick MJ, Mazurek RP, et al. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol. 1992;19(4):851–855.
   PubMed Web of Science ®Google Scholar
• Palomäki A, Mustonen P, Hartikainen JEK, et al. Strokes after cardioversion of atrial fibrillation — the FibStroke study. Int J Cardiol. 2016;203:269–273.
   PubMed Web of Science ®Google Scholar
• Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417–427.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:38.
   Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2014;64(21):e1–e76.
   PubMed Web of Science ®Google Scholar
• Rozen G, Hosseini SM, Kaadan MI, et al. Emergency department visits for atrial fibrillation in the United States: trends in admission rates and economic burden from 2007 to 2014. J Am Heart Assoc. 2018;7(15):15.
   Web of Science ®Google Scholar
• Barbic D, Dewitt C, Harris D, et al. Implementation of an emergency department atrial fibrillation and flutter pathway improves rates of appropriate anticoagulation, reduces length of stay and thirty-day revisit rates for congestive heart failure. Can J Emerg Med. 2018;20(3):392–400.
   Web of Science ®Google Scholar
• Kuppahally SS, Foster E, Shoor S, et al. Short-term and long-term success of electrical cardioversion in atrial fibrillation in managed care system. Int Arch Med. 2009;2(1):39.
   PubMedGoogle Scholar
• Burton JH, Vinson DR, Drummond K, et al. Electrical cardioversion of emergency department patients with atrial fibrillation. Ann Emerg Med. 2004;44(1):20–30.
   PubMed Web of Science ®Google Scholar
• Scheuermeyer FX, Grafstein E, Stenstrom R, et al. Thirty-day outcomes of emergency department patients undergoing electrical cardioversion for atrial fibrillation or flutter. Acad Emerg Med. 2010;17(4):408–415.
   PubMed Web of Science ®Google Scholar
• Grönberg T, Hartikainen JEK, Nuotio I, et al. Can we predict the failure of electrical cardioversion of acute atrial fibrillation? The FinCV study. Pacing Clin Electrophysiol. 2015;38(3):368–375.
   PubMed Web of Science ®Google Scholar
• Pisters R, Nieuwlaat R, Prins MH, et al. Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro heart survey. Europace. 2012;14(5):666–674.
   PubMed Web of Science ®Google Scholar
• Bellone A, Etteri M, Vettorello M, et al. Cardioversion of acute atrial fibrillation in the emergency department: a prospective randomised trial. Emerg Med J. 2012;29(3):188–191.
   PubMed Web of Science ®Google Scholar
• Michael JA, Stiell IG, Agarwal S, et al. Cardioversion of paroxysmal atrial fibrillation in the emergency department. Ann Emerg Med. 1999;33(4):379–387.
   PubMed Web of Science ®Google Scholar
• Hellman T, Kiviniemi T, Vasankari T, et al. Prediction of ineffective elective cardioversion of atrial fibrillation: a retrospective multi-center patient cohort study. BMC Cardiovasc Disord. 2017;17(1):33.
   PubMedGoogle Scholar
• Elhendy A, Gentile F, Khandheria BK, et al. Predictors of unsuccessful electrical cardioversion in atrial fibrillation. Am J Cardiol. 2002;89(1):83–86.
   PubMed Web of Science ®Google Scholar
• Alegret JM, Viñolas X, Sagristá J, et al. Predictors of success and effect of biphasic energy on electrical cardioversion in patients with persistent atrial fibrillation. Europace. 2007;9(10):942–946.
   PubMed Web of Science ®Google Scholar
• Hellman T, Kiviniemi T, Nuotio I, et al. Optimal timing for cardioversion in patients with atrial fibrillation. Clin Cardiol. 41(7): 966–971. 2018.
   PubMed Web of Science ®Google Scholar
• Pluymaekers NAHA, Dudink EAMP, Luermans JGLM, et al. Early or delayed cardioversion in recent-onset atrial fibrillation. N Engl J Med. 380(16): 1499–1508. 2019.
   PubMed Web of Science ®Google Scholar
• Conde D, Costabel JP, Caro M, et al. Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation. Int J Cardiol. 2013;168(3):2423–2425.
   PubMed Web of Science ®Google Scholar
• Pohjantähti-Maaroos H, Hyppölä H, Lekkala M, et al. Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation. Eur Heart J Acute Cardiovasc Care. 2019;8(2):114–120.
   PubMed Web of Science ®Google Scholar
• Lindberg S, Hansen S, Nielsen T. Spontaneous conversion of first onset atrial fibrillation. Intern Med J. 2012;42(11):1195–1199.
   PubMed Web of Science ®Google Scholar
• Danias PG, Caulfield TA, Weigner MJ, et al. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol. 1998;31(3):588–592.
   PubMed Web of Science ®Google Scholar
• Boriani G, Biffi M, Capucci A, et al. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease: a randomized, controlled trial. Ann Intern Med. 1997. DOI:10.7326/0003-4819-126-8-199704150-00006.
   PubMed Web of Science ®Google Scholar
• Jaakkola S, Lip GYH, Biancari F, et al. Predicting unsuccessful electrical cardioversion for acute atrial fibrillation (from the AF-CVS score). Am J Cardiol. 119(5): 749–752. 2017.
   PubMed Web of Science ®Google Scholar
• Wijffels MCEF, Kirchhof CJHJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation. 1995;92(7):1954–1968.
   PubMed Web of Science ®Google Scholar
• Wijffels MCEF, Kirchhof CJHJ, Dorland R, et al. Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation. 1997 Nov 18;96(10):3710–3720.
   PubMed Web of Science ®Google Scholar
• Dzeshka MS, Lip GYH, Snezhitskiy V, et al. Cardiac fibrosis in patients with atrial fibrillation: mechanisms and clinical implications. J Am Coll Cardiol. 2015;66(8):943–959.
   PubMed Web of Science ®Google Scholar
• Strandberg M, Raatikainen MJP, Niemelä M, et al. Clinical practicality and predictive value of transoesophageal echocardiography in early cardioversion of atrial fibrillation. Europace. 2006;8(6):408–412.
   PubMed Web of Science ®Google Scholar
• Frick M, Frykman V, Jensen-Urstad M, et al. Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. Clin Cardiol. 2001;24(3):238–244.
   PubMed Web of Science ®Google Scholar
• Raitt MH, Volgman AS, Zoble RG, et al. Prediction of the recurrence of atrial fibrillation after cardioversion in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2006;151(2):390–396.
   PubMed Web of Science ®Google Scholar
• Melduni RM, Lee HC, Bailey KR, et al. Real-time physiologic biomarker for prediction of atrial fibrillation recurrence, stroke, and mortality after electrical cardioversion: a prospective observational study. Am Heart J. 2015;170(5):914–922.
   PubMed Web of Science ®Google Scholar
• Weigner MJ, Thomas LR, Patel U, et al. Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year. Am J Med. 2001;110(9):694–702.
   PubMed Web of Science ®Google Scholar
• Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 344(19): 1411–1420. 2001.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22(8):983–988.
   PubMed Web of Science ®Google Scholar
• Hinton RC, Kistler JP, Fallon JT, et al. Influence of etiology of atrial fibrillation on incidence of systemic embolism. Am J Cardiol. 1977;40(4):509–513.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Nakamura K, Fukushima-Kusano K, et al. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb Res. 2003;111(3):137–142.
   PubMed Web of Science ®Google Scholar
• Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace. 2016;63(1):493–505.
   Google Scholar
• Fukuchi M, Watanabe J, Kumagai K, et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol. 2001;37(5):1436–1442.
   PubMed Web of Science ®Google Scholar
• Freestone B, Chong AY, Lim HS, et al. Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis? Ann Med. 2005;37(5):365–372.
   PubMed Web of Science ®Google Scholar
• Khan IA. Atrial stunning: basics and clinical considerations. Int J Cardiol. 2003;92(2–3):113–128.
   PubMed Web of Science ®Google Scholar
• Grimm RA, Stewart WJ, Maloney JD, et al. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol. 1993;22(5):1359–1366.
   PubMed Web of Science ®Google Scholar
• Stoddard MF, Dawkins PR, Prince CR, et al. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol. 1995;25(2):452–459.
   PubMed Web of Science ®Google Scholar
• Kleemann T, Becker T, Strauss M, et al. Prevalence of left atrial thrombus and dense spontaneous echo contrast in patients with short-term atrial fibrillation < 48 hours undergoing cardioversion: value of transesophageal echocardiography to guide cardioversion. J Am Soc Echocardiogr. 2009;22(12):1403–1408.
   PubMed Web of Science ®Google Scholar
• Jaakkola S, Kiviniemi TO, Airaksinen KEJ. Cardioversion for atrial fibrillation - how to prevent thromboembolic complications? Ann Med. 2018;50(7):549–555.
   PubMed Web of Science ®Google Scholar
• Andò G, Trio O. New oral anticoagulants versus warfarin in patients undergoing cardioversion of atrial fibrillation. Int J Cardiol. 2016;225:244–246.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation. 2011;123(10):e269–367.
   PubMed Web of Science ®Google Scholar
• Airaksinen KEJ. Cardioversion of atrial fibrillation and oral anticoagulation. J Atr Fibrillation. 2015. DOI:10.4022/jafib.1260
   PubMedGoogle Scholar
• Weigner MJ, Caulfield TA, Danias PG, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997;126(8):615–620.
   PubMed Web of Science ®Google Scholar
• Stiell IG, Birnie D. Managing recent-onset atrial fibrillation in the emergency department. Ann Emerg Med. 2011;57(1):31–32.
   PubMedGoogle Scholar
• Gallagher MM, Hennessy BJ, Edvardsson N, et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol. 2002;40(5):926–933.
   PubMed Web of Science ®Google Scholar
• Grönberg T, Hartikainen JEK, Nuotio I, et al. Anticoagulation, CHA2DS2VASc score, and thromboembolic risk of cardioversion of acute atrial fibrillation (from the FinCV study). Am J Cardiol. 2016;117(8):1294–1298.
   PubMed Web of Science ®Google Scholar
• Nuotio I, Hartikainen JEK, Grönberg T, et al. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. J Am Med Assoc. 2014;312(6):647–649.
   PubMed Web of Science ®Google Scholar
• Sohara H, Amitani S, Kurose M, et al. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol. 1997;29(1):106–112.
   PubMed Web of Science ®Google Scholar
• Lim HS, Willoughby SR, Schultz C, et al. Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm. J Am Coll Cardiol. 2013;61(8):852–860.
   PubMed Web of Science ®Google Scholar
• Fumagalli S, Boncinelli L, Bondi E, et al. Does advanced age affect the immediate and long-term results of direct-current external cardioversion of atrial fibrillation? J Am Geriatr Soc. 2002;50(7):1192–1197.
   PubMed Web of Science ®Google Scholar
• Goette A, Merino JL, Ezekowitz MD, et al. Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016;388(10055):1995–2003.
   PubMed Web of Science ®Google Scholar
• Cappato R, Ezekowitz MD, Klein AL, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346–3355.
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Pollack CV, Halperin JL, et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018;39(32):2959–2971.
   PubMed Web of Science ®Google Scholar
• Seidl K, Rameken M, Drögemüller A, et al. Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion: final results of the Ludwigshafen observational cardioversion study. J Am Coll Cardiol. 2002;39(9):1436–1442.
   PubMed Web of Science ®Google Scholar
• Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol. 1998;82(12):1545–1547.
   PubMed Web of Science ®Google Scholar
• Hansen ML, Jepsen RMHG, Olesen JB, et al. Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. EP Eur. 2015;17(1):18–23.
   PubMed Web of Science ®Google Scholar
• Grönberg T, Nuotio I, Nikkinen M, et al. Arrhythmic complications after electrical cardioversion of acute atrial fibrillation: the FinCV study. Europace. 2013;15(10):1432–1435.
   PubMed Web of Science ®Google Scholar
• Morani G, Cicoira M, Pozzani L, et al. Outpatient electrical cardioversion of atrial fibrillation: 8 years’ experience. Analysis of shock-related arrhythmias. Pacing Clin Electrophysiol. 2009;32(9):1152–1158.
   PubMed Web of Science ®Google Scholar
• Jaakkola J, Hartikainen JEK, Kiviniemi T, et al. Ventricular rate during acute atrial fibrillation and outcome of electrical cardioversion: the FinCV Study. Ann Med. 2015;47(4):341–345.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation. 2019;140(2):e125–e151.
   PubMed Web of Science ®Google Scholar
• Andrade JG, MacGillivray J, Macle L, et al. Clinical effectiveness of a systematic “pill-in-the-pocket” approach for the management of paroxysmal atrial fibrillation. Heart Rhythm. 2018;15(1):9–16.
   PubMed Web of Science ®Google Scholar